# Pizarra — PT-pseudo_d5ceb6b4204f (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_d5ceb6b4204f
Task: 1

Encounter: Urology - outpatient on 13 Jan 2025.
Referrer: Dr. C. Peters (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 72-year-old male
  - PSA: 4.1 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.181 ng/mL²
  - PSA velocity: 0.77 ng/mL/yr
  - Prior PSA: 3.3 ng/mL
  - Prostate volume: 22.65 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8003183 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 4.1 ng/mL. PI-RADS 4. PSAD 0.18. Prostate volume 23 mL. csPCa 0.80.

Vitals: weight 90 kg, height 173 cm, BMI 30.1, BP 130/80 mmHg, HR 58 bpm. Smoking: Ex-smoker (10 pack-yr, quit 2021).

Chief complaint: Clinical reassessment prompted by a PSA increase to 4.1 ng/mL alongside a previously confirmed positive biopsy result.

History: A 72-year-old retired bus driver, widowed, entered the workup for a PSA elevation in mid-2023, a value that has now climbed to 4.1 ng/mL. He resides in an assisted-living facility situated over 90 minutes from the hospital, prompting a preference for telephone monitoring when clinically suitable. Despite his years, his lifestyle remains vigorous; he jogs 5 km three times each week and experiences only slight urinary bother, scoring a 7 on the IPSS. Tobacco use ceased entirely in 2021 after accumulating 10 pack-years, and he avoids alcohol. No comorbidities are present, and he takes no medications. Unrelated recent medical encounters include a dermatology visit for actinic keratosis monitoring and a completed six-session physiotherapy regimen addressing mechanical lower back pain. He maintains baseline functionality without systemic complaints.

Physical examination: DRE — texture: uniformly smooth; mobility: unrestricted; asymmetry: absent. The prostate appears symmetrically benign with no palpable nodules, confirming a normal digital rectal assessment. General inspection shows a well-nourished gentleman free of acute distress, maintaining stable vital signs and clear breath sounds. Abdominal palpation yields no masses or organomegaly, remaining entirely unremarkable.

Patient info: retired bus driver; Widowed; Lives in assisted-living facility.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Running 3x/week, 5 km; IPSS score: 7/35 (mild LUTS).

Recent other appointments: Dermatology — actinic keratosis check; Physiotherapy — lower back, six sessions.
Admin: Lives >90 min from clinic; phone follow-up preferred where clinically safe.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.58 +/- 0.19   (95% CI 0.19-0.91)

Where the uncertainty comes from:
  - aleatoric  dA = 0.15  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.12  (few labelled cases resemble this one)
  - 6.9 effective neighbours out of 10; 4 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {no, yes}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=4.0, bx_ord=3.0, psa=4.1, age=72.0, psad=0.181, dre_ord=0.0, vol=22.65, n_pmhx=0.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
  The statistical recommender relied only on the structured panel. It could not weigh the PSA velocity (0.77 ng/mL/yr) against the prior PSA (3.3 ng/mL) to assess the rate of change, which is a critical dynamic factor. It also could not incorporate the specific details from the mpMRI report (beyond the PI-RADS 4) or the full laboratory panel, which might contain markers influencing the csPCa probability or PSA density interpretation. Finally, it did not see the context of the prior positive biopsy result when assessing the current decision point.

WHY THE SUGGESTION COULD BE WRONG
  The prior suggests a 'discuss' tier decision (0.58 +/- 0.19). A failure mode is the high csPCa predicted probability (0.8003183) conflicting with the normal DRE and the PI-RADS 4 score, suggesting the prior might be overly cautious or misweighting the risk. Another failure mode is the prior positive biopsy result; if the current PSA rise is deemed clinically insignificant given the prior diagnosis, the recommendation for biopsy might be inappropriate. The wide error bar (0.19) indicates high uncertainty, meaning the prior's suggestion is highly susceptible to missing context.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
  <document> -> radiology / mpMRI report -> If the report details significant intraprostatic extension or high-risk features, it would increase the need for biopsy.
  <document> -> PSA history (trend) -> If the PSA velocity is significantly higher than the prior, it would increase the urgency for a decision.
  <document> -> previous GP / urology consultation notes -> These notes might clarify the clinical significance of the prior positive biopsy result in the context of the current PSA.
  <document> -> laboratory results (full panel) -> This could provide additional biomarkers that modify the risk assessment derived from the PI-RADS and PSA values.

## [4] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
  One block per document you opened. Quote the values and phrases that matter, verbatim and with units. Numbers, lesion descriptions, dates, explicit radiologist or clinician recommendations. Do not paraphrase a number. If a document turned out to be uninformative, say so in one line.

  **radiology / mpMRI report**
  {"case_id": "PT-pseudo_d5ceb6b4204f", "radiology_report": "Subject: Multiparametric MRI of the Prostate | Date: 10 Jan 2025 | Facility: Amsterdam UMC (AMC campus)\n\nClinical indication: Surveillance after a previously positive biopsy; current PSA stands at 4.1 ng/mL with clinical suspicion for clinically significant disease.\n\nFINDINGS:\nThe gland measures 22.65 mL in volume. T2-weighted sequences highlight an asymmetric focal hypointensity in the right mid-gland peripheral zone, spanning roughly 12 mm. Diffusion-weighted imaging shows marked restriction, mirrored by correspondingly low apparent diffusion coefficient values. Dynamic contrast enhancement demonstrates early, focal uptake compared to adjacent tissue. There is no evidence of extraprostatic extension or seminal vesicle invasion. The central zone appears normal without notable benign enlargement. Pelvic lymph nodes are unremarkable. Skeletal survey reveals no suspicious osseous abnormalities.\n\nIMPRESSION:\nPI-RADS 4 lesion situated in the right mid-gland peripheral zone.\nProstate volume 22.65 mL; PSA density 0.181 ng/mL/mL.\ncsPCa predicted probability 0.8003183."}

  **psa_trend**
  {"case_id": "PT-pseudo_d5ceb6b4204f", "psa_trend": [{"date": "Jul 2023", "val": 1.0}, {"date": "Jan 2024", "val": 1.2}, {"date": "Jul 2024", "val": 3.4}, {"date": "Jan 2025", "val": 4.1}]}

  **previous_notes**
  {"case_id": "PT-pseudo_d5ceb6b4204f", "previous_notes": [{"date": "18 May 2024", "author": "Dr. C. Peters (GP)", "text": "18 May 2024 - Dr. C. Peters (GP)\nConsultation focused on tracking the ascending PSA trajectory. An earlier reading from July 2023 recorded 1.7 ng/mL, followed by a January 2024 measurement of 2.2 ng/mL. The individual notes stable, mild lower urinary tract complaints while continuing a consistent running schedule. Laboratory panels were ordered to track the progression, and a specialist urology referral was processed given the steady increase and the history of a previously positive biopsy."}, {"date": "23 Jul 2023", "author": "Dr. C. Peters (GP)", "text": "23 Jul 2023 - Dr. C. Peters (GP)\nStandard check-in following the first PSA elevation. The latest result measures 1.7 ng/mL, sitting just above the standard laboratory reference range. Urinary function remains unaffected, and he continues residing in his assisted-living residence. A follow-up PSA test was planned for January to calculate velocity, accompanied by routine metabolic panels."}]}

  **laboratory_results**
  {"case_id": "PT-pseudo_d5ceb6b4204f", "laboratory_results": [{"name": "PSA", "val": "4.1 ng/mL", "date": "30 Nov 2024", "flag": "H"}, {"name": "Free PSA", "val": "0.48 ng/mL", "date": "30 Nov 2024", "flag": ""}, {"name": "%Free PSA", "val": "12%", "date": "30 Nov 2024", "flag": "L"}, {"name": "Haemoglobin", "val": "14.3 g/dL", "date": "30 Nov 2024", "flag": ""}, {"name": "WBC", "val": "7.0 x10^9/L", "date": "30 Nov 2024", "flag": ""}, {"name": "Platelets", "val": "153 x10^9/L", "date": "30 Nov 2024", "flag": ""}, {"name": "Creatinine", "val": "81 umol/L", "date": "30 Nov 2024", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "30 Nov 2024", "flag": ""}, {"name": "Testosterone", "val": "13.3 nmol/L", "date": "30 Nov 2024", "flag": ""}, {"name": "Alkaline phosphatase", "val": "68 U/L", "date": "30 Nov 2024", "flag": ""}, {"name": "LDH", "val": "185 U/L", "date": "30 Nov 2024", "flag": ""}]}

NOT RETRIEVED
  get_family_history: Not called because the retrieval economy suggests it is not necessary for this specific decision point based on the other retrieved data.

WHAT THE EVIDENCE SUPPORTS
  FOR sampling this patient now:
  - PI-RADS 4 lesion situated in the right mid-gland peripheral zone
  - PSA velocity is high: The PSA increased from 3.4 ng/mL (Jul 2024) to 4.1 ng/mL (Jan 2025), indicating a significant rise in the last 6 months.
  - csPCa predicted probability is high: 0.8003183

  AGAINST sampling this patient now:
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - No evidence of extraprostatic extension or seminal vesicle invasion on MRI.
  - Prior biopsy was positive.

WHERE THIS LEANS
  The retrieved evidence strongly argues for further investigation due to the high PI-RADS score, the significant PSA velocity, and the high predicted csPCa probability, which aligns with the statistical prior's suggestion to biopsy.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [5] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [6] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

Biopsy is recommended because the evidence strongly supports further investigation due to the PI-RADS 4 lesion, the significant PSA velocity (increase from 3.4 to 4.1 ng/mL), and the high csPCa predicted probability of 0.8003183. This decision is reinforced by the prior positive biopsy result, which mandates re-evaluation when dynamic factors suggest progression.

Variables that carried weight: bx=decisive, dre=noted, psa=decisive, psad=important, pirads=decisive
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
